Targets › CCR5
10 programs from 8 companies in 12 trials: 8 Phase 2, 4 Phase 1; Infectious disease, Oncology, Neurology; next expected readout Nov 2026.
Receptor for a number of inflammatory CC-chemokines including CCL3/MIP-1-alpha, CCL4/MIP-1-beta and RANTES and subsequently transduces a signal by increasing the intracellular calcium ion level. May play a role in the control of granulocytic lineage proliferation or differentiation. (UniProt, P51681)
Open in Phaseline: the race on CCR5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Icahn School of Medicine at Mount Sinai | Maraviroc C-C chemokine receptor type 5 antagonist | CCR5 | Phase 2 | Long Covid | Nov 2026 |
| Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | maraviroc C-C chemokine receptor type 5 antagonist | CCR5 | Phase 2 | HIV-1-infection | Jun 2027 |
| Emmanuel Carrera | Maraviroc C-C chemokine receptor type 5 antagonist | CCR5 | Phase 2 | Ischemic Stroke | Dec 2027 |
| CytoDyn | leronlimab C-C chemokine receptor type 5 antagonist | CCR5 | Phase 2 | Metastatic Colorectal Cancer (mCRC); HIV - Human Immunodeficiency Virus; Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease | Jan 2028 |
| Icahn School of Medicine at Mount Sinai | BMS-813160 C-C chemokine receptor type 2 antagonist; C-C chemokine receptor type 5 antagonist | CCR2, CCR5 | Phase 2 | Non-small Cell Lung Cancer | Jul 2028 |
| QuantumLeap Healthcare Collaborative | Cenicriviroc C-C chemokine receptor type 5 antagonist; C-C chemokine receptor type 2 antagonist | CCR5, CCR2 | Phase 2 | COVID-19 | Jul 2028 |
| City of Hope Medical Center | lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells lentivirus-transduced hematopoietic progenitor cells expressing anti-HIV shRNA targeting T | CCR5 | Phase 1 | AIDS-related Non-Hodgkin Lymphoma | Jul 2027 |
| City of Hope Medical Center | SB-728mR-HSPC Zinc finger nuclease-mediated CCR5 disruption in hematopoietic stem/progenitor cells | CCR5 | Phase 1 | HIV | Jul 2027 |
| National Cancer Institute (NCI) | Maraviroc C-C chemokine receptor type 5 antagonist | CCR5 | Phase 1 | HIV | Jul 2027 |
| AIDS Malignancy Consortium | Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-pos Gene therapy using lentiviral vector expressing CCR5 shRNA, TRIM5alpha, and TAR decoy in a | CCR5, TRIM5 | Phase 1 | HIV Infection | Mar 2036 |
HIV (2) Ischemic Stroke (1) Non-small Cell Lung Cancer (1) AIDS-related Non-Hodgkin Lymphoma (1) COVID-19 (1) HIV Infection (1) HIV-1-infection (1) Long Covid (1) Metastatic Colorectal Cancer (mCRC) (1) HIV - Human Immunodeficiency Virus (1) Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (1)
small molecule (4), mixed (4), antibody (1), other (1)
Icahn School of Medicine at Mount Sinai (2) City of Hope Medical Center (2) Emmanuel Carrera (1) QuantumLeap Healthcare Collaborative (1) National Cancer Institute (NCI) (1) AIDS Malignancy Consortium (1) Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal (1) CytoDyn (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.